News
Abbott Declares 405th Consecutive Quarterly Dividend
ABBOTT PARK, Ill., Feb. 21, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 59 cents per share. This marks the 405th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May 15, 2025, to shareholders of record at the close of business on April 15, 2025. Abbott has increased its dividend payout for 53 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks...
Abbott Declares 406th Consecutive Quarterly Dividend
ABBOTT PARK, Ill., June 13, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 59 cents per share. This marks the 406th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug. 15, 2025, to shareholders of record at the close of business on July 15, 2025. Abbott has increased its dividend payout for 53 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks...
Abbott HeartMates Community Delivers Holiday Cheer in Hallmark Channel's New Movie "The More the Merrier"
Movie to feature cameos from youth who have overcome significant heart health challenges and are part of the Abbott HeartMates community as well as professional football player and HeartMates ambassador Damar Hamlin "The More the Merrier" is the first Hallmark movie ever to include cameos from real-life individuals who have overcome cardiovascular challenges Character in the movie was inspired by Abbott HeartMates member Zeke Mankins, who has established a friendship with Hamlin through...
Abbott Highlights New AVEIR™ Data, Initiates Trial for the Company's Conduction System Pacing Technology
Late-breaking data from Abbott's groundbreaking first-in-human study demonstrated successful implantation of the company's AVEIR Conduction System Pacing (CSP) leadless pacemaker Enrollment has also begun in the ASCEND CSP pivotal clinical trial to evaluate Abbott's investigational CSP Implantable Cardioverter-Defibrillator (ICD) lead Conduction System Pacing is an evolving technique specifically designed to deliver pacing to the left bundle branch area of the heart to restore its natural...
Abbott Hosts Conference Call for First-Quarter Earnings
ABBOTT PARK, Ill., March 26, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2025 financial results on Wednesday, April 16, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott: Abbott is a global...
Abbott Hosts Conference Call for Fourth-Quarter Earnings
ABBOTT PARK, Ill., Jan. 2, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2024 financial results on Wednesday, Jan. 22, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8:30 a.m. Central time (9:30 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott: Abbott is a global...
Abbott Hosts Conference Call for Second-Quarter Earnings
ABBOTT PARK, Ill., June 26, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2025 financial results on Thursday, July 17, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott: Abbott is a global...
Abbott Hosts Conference Call for Third-Quarter Earnings
ABBOTT PARK, Ill., Sept. 24, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2025 financial results on Wednesday, Oct. 15, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at https://www.abbott.com/investors.html. An archived edition of the call will be available later that day. About Abbott: Abbott is a...
Abbott Initiates New Intravascular Lithotripsy Clinical Trial to Improve Outcomes in Patients with Coronary Artery Disease
Coronary Artery Disease (CAD) is the most common heart disease and most frequent cause of death in the U.S., with over 20 million adults affected by this condition Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System offers a new potential treatment by using sound pressure waves to treat arterial calcium blockages Abbott offers a comprehensive vascular portfolio of technologies designed to assess, treat and manage calcium buildup in coronary arteries ABBOTT PARK, Ill.,...
Abbott Integrates Libre's Data with Epic's Electronic Health Record System, Providing Healthcare Professionals Seamless Glucose Monitoring Information
Collaboration brings together FreeStyle Libre(R) Systems, the world's leading continuous glucose monitoring technology (CGM)1 with Epic, a healthcare software company, to streamline access to CGM data for healthcare organizations Integration empowers U.S. clinicians to enhance patient care by incorporating Libre's data directly into their workflows ABBOTT PARK, Ill., April 29, 2025 /PRNewswire/ -- Abbott (NYSE: ABT), the global leader in continuous glucose monitoring (CGM) biowearable...
Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms
Abbott's Volt(TM) PFA System is designed to provide a new therapy option for people battling heart rhythm disorders such as atrial fibrillation Pulsed field ablation - or PFA - uses high energy electrical pulses for ablation procedures that may offer benefits to targeting and treating tissue in the heart Abbott's Volt PFA System is designed to overcome limitations of existing PFA systems, providing improved workflows and a clearer indication of contact between the Volt PFA catheter and...
Abbott Receives FDA Approval for Tendyne™, First-of-Its-Kind Device to Replace the Mitral Valve Without Open-Heart Surgery
The Tendyne system replaces mitral valves that are not functioning properly due to a buildup of calcium in the base of the valves, known as severe mitral annular calcification (MAC) Tendyne offers a new treatment option for patients who are not candidates for open-heart surgery or mitral repair This approval expands Abbott's portfolio of minimally invasive structural heart therapies in the U.S. ABBOTT PARK, Ill., May 27, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the U.S. Food...
Abbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance
First-quarter GAAP diluted EPS of $0.76; adjusted diluted EPS of $1.09 First-quarter reported sales growth of 4.0 percent; organic sales growth of 6.9 percent or 8.3 percent when excluding COVID-19 testing-related sales1 Reported gross margin of 52.8 percent of sales; adjusted gross margin of 57.1 percent, which reflects a 140 basis point increase Reported operating margin of 16.3 percent of sales; adjusted operating margin of 21.0 percent, which reflects a 130 basis point increase ABBOTT...
Abbott Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Financial Outlook
Fourth-quarter sales of $11.0 billion; full-year 2024 sales of $42.0 billion Fourth-quarter reported sales increased 7.2 percent; organic sales growth for the underlying base business increased 10.1 percent1 Full-year 2024 reported sales increased 4.6 percent; organic sales growth for the underlying base business increased 9.6 percent2 Abbott projects full-year 2025 organic sales growth to be in the range of 7.5% to 8.5% ABBOTT PARK, Ill., Jan. 22, 2025 /PRNewswire/ -- Abbott (NYSE: ABT)...
Abbott Reports Second-Quarter 2025 Results
Second-quarter reported sales growth of 7.4 percent; organic sales growth of 6.9 percent or 7.5 percent excluding COVID-19 testing-related sales1 Second-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.26 Reported gross margin of 52.7 percent of sales; adjusted gross margin of 57.0 percent, which reflects a 100 basis point increase Reported operating margin of 18.4 percent of sales; adjusted operating margin of 22.9 percent, which reflects a 100 basis point increase ABBOTT PARK,...
Abbott Reports Third-Quarter 2025 Results and Reaffirms Full-Year Guidance
Third-quarter reported sales growth of 6.9 percent; organic sales growth of 5.5 percent or 7.5 percent excluding COVID-19 testing-related sales1 Third-quarter GAAP diluted EPS of $0.94; adjusted diluted EPS of $1.30 Reported operating margin of 18.1 percent of sales; adjusted operating margin of 23.0 percent, which reflects a 40 basis point increase ABBOTT PARK, Ill., Oct. 15, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2025....
Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent
This summer, Abbott and Real Madrid are hosting tryouts across the U.S. to form the 'Abbott Dream Team' Tryout attendees will learn about health and sports nutrition, encouraging them to promote healthy habits and an active lifestyle in their communities Eleven selected players will travel to Madrid, train at Real Madrid's world-class facilities, and be instructed by Real Madrid coaches American soccer icon Clint Dempsey will mentor the athletes throughout their journey ABBOTT PARK, Ill., May...
Abbott increases quarterly dividend for 54th consecutive year
Quarterly dividend increased by 6.8% Quarterly dividend payout has increased more than 70% since 2020 408th consecutive quarterly dividend to be paid by Abbott since 1924 ABBOTT PARK, Ill., Dec. 12, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 63 cents per share, an increase of 6.8%. The company's quarterly dividend payout has increased more than 70% since 2020. This marks Abbott's 54th consecutive...
Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments
Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments Acquisition will uniquely position Abbott to transform cancer care, advancing earlier detection and optimizing treatment and monitoring to help millions more people live healthier lives Exact Sciences' product lines feature advanced cancer screening and diagnostic solutions, including...
Abbott's 'Above the Bias' Film Reveals Misconceptions Can Impact Diabetes Care
New survey shows 40 per cent of people living with diabetes have skipped or missed a doctor's appointment due to shame or stigma1 70 per cent of people living with diabetes said supportive comments from others can significantly boost their motivation to manage their condition1 Abbott launches film that highlights challenges of living life with diabetes MISSISSAUGA, ON, Feb. 4, 2025 /CNW/ -- 'One cupcake won't kill you', 'I'm going to get diabetes just looking at that', 'That person doesn't...
Abbott's Amplatzer Piccolo™ Delivery System Receives FDA Clearance and CE Mark to Optimize Procedures for Premature Babies With a Hole in the Heart
First and only delivery system designed specifically for premature infants with a patent ductus arteriosus (PDA), a life-threatening opening in their heart New delivery system enables precise placement of Abbott's Amplatzer Piccolo Occluder in the tiniest babies A PDA requiring treatment is present in approximately 20% of premature infants1 ABBOTT PARK, Ill., Dec. 18, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) clearance and...
Abbott's Libre® Technology is First Continuous Glucose Monitor Associated with Reduced Hospitalizations for Heart Complications in People with Diabetes
New data reveal a 78% reduction in cardiovascular disease-related hospitalizations for people living with Type 1 diabetes with prior severe low blood sugar episodes.1 This significant decrease is linked to the use of Libre biowearable technology compared to traditional blood glucose monitors.1 Results also show a reduction in hospitalization for cardiovascular complications in adults with Type 2 diabetes on insulin using Libre technology.2 ABBOTT PARK, Ill., May 15, 2025 /PRNewswire/ --...
Abbott's Lingo™ Now on Android™, Expanding Access to Real-Time Glucose Data
Lingo, Abbott's first over-the-counter biowearable, expands to Android devices Continuous glucose monitoring devices help people maintain healthy glucose levels, which are associated with better metabolic health and lower long-term risk of chronic conditions New data from Lingo users highlight how protein supplementation is linked to lower glucose in people who use continuous glucose monitors, especially for people with obesity, a group at higher risk for prediabetes, type 2 diabetes and...
Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation
Abbott's Volt(TM) PFA System, the latest generation of cardiac ablation technology, is designed for people battling heart rhythm disorders such as atrial fibrillation (AFib) Pulsed field ablation - or PFA - is a minimally invasive procedure that uses high-energy electrical pulses in targeted areas of the heart to treat irregular heart rhythms Abbott's Volt PFA System is an all-in-one product that is clinically proven to simplify the treatment of AFib that is gentler on the heart, has shorter...
MotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test for Concussion Evaluation On-site at Races
The test, run on Abbott's portable i-STAT(R) Alinity(R) hand-held instrument, uses whole blood to help evaluate patients 18 years of age and older with a suspected mild traumatic brain injury, or concussion, producing lab-quality results in 15 minutes The test will be used by healthcare professionals in the medical facilities at all MotoAmerica races in 2025 ABBOTT PARK, Ill., and IRVINE, Calif., May 1, 2025 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare company, and MotoAmerica,...
Muscles, the New Flex: Abbott Launches Two New Ensure® Max Protein Shakes to Tap into Growing Muscle Health Movement
Aging, nutrition and lifestyle affect muscles, especially after age 40. That's why Matt Ryan, former professional quarterback and MVP, is teaming up with Abbott to drive muscle health awareness with two new Ensure Max Protein shakes Ensure Max Protein 42g: For physically active adults, this new shake delivers 42 grams of complete protein to help build muscle tissue alongside resistance training with 23 vitamins and minerals and two key electrolytes to support muscle function Ensure Max...
New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib
Long-term data from the Volt CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt(TM) PFA System The 12-month results of the Volt CE Mark Study confirm the long-term safety and efficacy of the Volt PFA System The data were presented at the 2025 Heart Rhythm Society (HRS) annual meeting ABBOTT PARK, Ill., April 26, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) has announced new data from its Volt CE Mark Study that show strong...
New Late-Breaking Data Reinforce Benefits of Abbott's TriClip™ for People With Leaky Tricuspid Heart Valve
TRILUMINATE(TM) Pivotal data presented at the American College of Cardiology's Annual Scientific Session (ACC.25) and simultaneously published in Circulation show the Abbott TriClip system reduces heart failure hospitalizations The latest results highlight significant improvements in tricuspid regurgitation and quality of life through two years ABBOTT PARK, Ill., March 31, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data from its TRILUMINATE(TM) Pivotal trial that...
New Research on Abbott's Healthy Food Rx Program Shows 'Food is Medicine' Approach Helps People Living With Diabetes Eat Better and Feel Healthier
Randomized, controlled clinical trial presented as a late-breaking poster at ADA's Scientific Sessions shows people participating in Abbott's Healthy Food Rx ate more vegetables and fruit, and reported significantly improved health status. Abbott's Healthy Food Rx community-focused "food is medicine" program provides home-delivered healthy food boxes and nutrition education in Stockton, Calif., where 60% of the population has diabetes or pre-diabetes. CHICAGO, June 20, 2025 /PRNewswire/ --...
University of Wisconsin Wins Abbott and Big Ten's 'We Give Blood' Competition as Campaign Donations Surge 319%, Helping Save Nearly 250,000 Lives
University of Wisconsin wins Abbott and the Big Ten Conference's "We Give Blood" drive, awards $1 million from Abbott to advance student or community health Second year of nationwide blood drive saw a 319% increase in overall participation with 83,043 donations and a 168% jump in student donors compared to 2024 Big Ten students, alumni, and fans helped save up to 250,000 lives during the college football season A recent 'We Give Blood' survey found 92% of participants are very likely to...